Xu Han

9.4k total citations · 1 hit paper
77 papers, 3.2k citations indexed

About

Xu Han is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Xu Han has authored 77 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Molecular Biology, 27 papers in Cancer Research and 10 papers in Oncology. Recurrent topics in Xu Han's work include RNA modifications and cancer (19 papers), Cancer-related molecular mechanisms research (17 papers) and MicroRNA in disease regulation (13 papers). Xu Han is often cited by papers focused on RNA modifications and cancer (19 papers), Cancer-related molecular mechanisms research (17 papers) and MicroRNA in disease regulation (13 papers). Xu Han collaborates with scholars based in China, Singapore and United States. Xu Han's co-authors include Wing‐Kin Sung, Yijun Ruan, Chia‐Lin Wei, Mengquan Li, Huck‐Hui Ng, Kuo Ping Chiu, Xiao Dong Zhao, Atif Shahab, Keke Miao and Yuriy L. Orlov and has published in prestigious journals such as Nature Communications, Molecular Cell and Bioinformatics.

In The Last Decade

Xu Han

74 papers receiving 3.2k citations

Hit Papers

Hybrid cellular membrane nanovesicles amplify macrophage ... 2020 2026 2022 2024 2020 100 200 300

Peers

Xu Han
Mohashin Pathan Australia
Xin Hu China
Tao Zhou China
Xiao Zhao China
Kai Xu China
Piotr Swiderski United States
Xu Han
Citations per year, relative to Xu Han Xu Han (= 1×) peers Lifeng Zhang

Countries citing papers authored by Xu Han

Since Specialization
Citations

This map shows the geographic impact of Xu Han's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xu Han with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xu Han more than expected).

Fields of papers citing papers by Xu Han

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xu Han. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xu Han. The network helps show where Xu Han may publish in the future.

Co-authorship network of co-authors of Xu Han

This figure shows the co-authorship network connecting the top 25 collaborators of Xu Han. A scholar is included among the top collaborators of Xu Han based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xu Han. Xu Han is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, Zhichao, Zhenyu Shi, Hanlian Liu, et al.. (2025). A soft receiving platform for coaxial bioprinting cell-laden microtubes with uniform wall thickness. Applied Materials Today. 42. 102599–102599. 2 indexed citations
2.
Huang, Zhiheng, et al.. (2025). Machine learning-based identification of co-expressed genes in prostate cancer and CRPC and construction of prognostic models. Scientific Reports. 15(1). 5679–5679. 7 indexed citations
3.
Han, Xu, et al.. (2024). MALAT1/miR-582-5p/GALNT1/MUC1 axis modulates progression of AML leukemia stem cells by regulating JAK2/STAT3 pathway. Annals of Hematology. 103(12). 5273–5283. 4 indexed citations
4.
Song, Liang, Ruoyang Liu, Yu Zhang, et al.. (2024). 8-Br-cGMP activates HSPB6 and increases the antineoplastic activity of quinidine in prostate cancer. Cell Death Discovery. 10(1). 90–90. 3 indexed citations
5.
Su, Qi, Kun Chen, Sze Wei Leong, et al.. (2024). Homoharringtonine promotes non-small-cell lung cancer cell death via modulating HIF-1α/ERβ/E2F1 feedforward loop. Journal of Pharmacy and Pharmacology. 76(12). 1647–1659.
6.
Duan, Fenghai, J.K. Chang, Zitao Liu, et al.. (2024). Deciphering endocrine function of adipose tissue and its significant influences in obesity-related diseases caused by its dysfunction. Differentiation. 141. 100832–100832. 4 indexed citations
7.
Liu, Xuefei, Xu Han, Guorong Li, et al.. (2022). Comprehensive Evaluation of the m6A Regulator Prognostic Risk Score in the Prediction of Immunotherapy Response in Clear Cell Renal Cell Carcinoma. Frontiers in Immunology. 13. 818120–818120. 6 indexed citations
8.
Zhang, Yue, Fanhong Zeng, Ming Zeng, et al.. (2021). Identification and Characterization of Alcohol-related Hepatocellular Carcinoma Prognostic Subtypes based on an Integrative N6-methyladenosine methylation Model. International Journal of Biological Sciences. 17(13). 3554–3572. 13 indexed citations
9.
Rao, Lang, Lei Wu, Zhida Liu, et al.. (2020). Hybrid cellular membrane nanovesicles amplify macrophage immune responses against cancer recurrence and metastasis. Nature Communications. 11(1). 4909–4909. 307 indexed citations breakdown →
10.
Zhang, Yue, Fanhong Zeng, Xu Han, Jun Weng, & Yi Gao. (2020). Lineage tracing: technology tool for exploring the development, regeneration, and disease of the digestive system. Stem Cell Research & Therapy. 11(1). 438–438. 18 indexed citations
11.
Han, Xu, et al.. (2019). MiR-889 promotes cell growth in human non-small cell lung cancer by regulating KLF9. Gene. 699. 94–101. 15 indexed citations
12.
Chi, Yan‐Yan, Xu Han, Feng Wang, et al.. (2018). ZKSCAN3 promotes breast cancer cell proliferation, migration and invasion. Biochemical and Biophysical Research Communications. 503(4). 2583–2589. 20 indexed citations
13.
Han, Xu, Mengquan Li, Yue Zhou, et al.. (2015). S100A4 participates in epithelial-mesenchymal transition in breast cancer via targeting MMP2. Tumor Biology. 37(3). 2925–2932. 31 indexed citations
14.
Sun, Ran, Yu‐Shui Ma, Shengyu Feng, et al.. (2014). Differential expression profiling of microRNAs in para-carcinoma, carcinoma and relapse human pancreatic cancer. Clinical & Translational Oncology. 17(5). 398–408. 8 indexed citations
15.
Gao, Ying, et al.. (2013). Expression of p114RhoGEF predicts lymph node metastasis and poor survival of squamous-cell lung carcinoma patients. Tumor Biology. 34(3). 1925–1933. 8 indexed citations
16.
Han, Xu, Xuefeng Fang, Xiaoyan Lou, et al.. (2012). Silencing SOX2 Induced Mesenchymal-Epithelial Transition and Its Expression Predicts Liver and Lymph Node Metastasis of CRC Patients. PLoS ONE. 7(8). e41335–e41335. 128 indexed citations
17.
Han, Xu & Wing‐Kin Sung. (2011). Identifying Differential Histone Modification Sites from ChIP‐seq Data. Methods in molecular biology. 802. 293–303. 10 indexed citations
18.
Li, Guoliang, Melissa J. Fullwood, Xu Han, et al.. (2010). ChIA-PET tool for comprehensive chromatin interaction analysis with paired-end tag sequencing. Genome biology. 11(2). R22–R22. 204 indexed citations
19.
Wang, Jun, Jiaofang Shao, Fan Mo, et al.. (2010). Identification of Novel SNPs by Next-Generation Sequencing of the Genomic Region Containing the APC Gene in Colorectal Cancer Patients in China. OMICS A Journal of Integrative Biology. 14(3). 315–325. 6 indexed citations
20.
Yao, Fei, Joshy George, Xu Han, et al.. (2007). Genome-wide Mapping of RELA(p65) Binding Identifies E2F1 as a Transcriptional Activator Recruited by NF-κB upon TLR4 Activation. Molecular Cell. 27(4). 622–635. 153 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026